Sort by
Previous Page Page 1 of 2 Next Page
  1. Methodology

    A new two-strip TLC method for the quality control of technetium-99m mercaptoacetyl-triglycine (99mTc-MAG3)

    99mTc-mercaptoacetyl-triglycine (99mTc-MAG3) has been used for dynamic renal imaging since about 30 years. Free pertechnetate (99mTcO4), colloidal 99mTc ((99mTcO2)n), 99mTc-tartrate (precursor), precomplexes (99m

    Marietta Straub, Michel Leresche, Claude Pilloud, Fabien Devynck, Nicolas Stritt and Rolf Hesselmann

    EJNMMI Radiopharmacy and Chemistry 2018 3:5

    Published on: 14 March 2018

  2. Review

    Production of novel diagnostic radionuclides in small medical cyclotrons

    The global network of cyclotrons has expanded rapidly over the last decade. The bulk of its industrial potential is composed of small medical cyclotrons with a proton energy below 20 MeV for radionuclides prod...

    Mateusz Adam Synowiecki, Lars Rutger Perk and J. Frank W. Nijsen

    EJNMMI Radiopharmacy and Chemistry 2018 3:3

    Published on: 20 February 2018

  3. Research article

    Radiosynthesis and evaluation of an 18F–labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma

    Analogues of exendin-4 have been radiolabeled for imaging the glucagon-like peptide type 1 receptors (GLP-1R) which are overexpressed in insulinoma. The aim of this research was to synthesize an 18F–labeled silic...

    Lukas O. Dialer, Andreas Jodal, Roger Schibli, Simon M. Ametamey and Martin Béhé

    EJNMMI Radiopharmacy and Chemistry 2018 3:1

    Published on: 2 January 2018

  4. Position Paper

    Generation of fluorescently labeled tracers – which features influence the translational potential?

    Given the increasing exploration of fluorescent tracers in the field of nuclear medicine, a need has risen for practical development guidelines that can help improve the translation aspects of fluorescent trac...

    Fijs W. B. van Leeuwen, Bart Cornelissen, Federico Caobelli, Laura Evangelista, Latifa Rbah-Vidal, Silvana Del Vecchio, Catarina Xavier, Jacques Barbet and Marion de Jong

    EJNMMI Radiopharmacy and Chemistry 2017 2:15

    Published on: 15 December 2017

  5. Research article

    Production and separation of 43Sc for radiopharmaceutical purposes

    The favorable decay properties of 43Sc and 44Sc for PET make them promising candidates for future applications in nuclear medicine. An advantage 43Sc (T1/2 = 3.89 h, Eβ+ av = 476 keV [8...

    Katharina A. Domnanich, Robert Eichler, Cristina Müller, Sara Jordi, Vera Yakusheva, Saverio Braccini, Martin Behe, Roger Schibli, Andreas Türler and Nicholas P. van der Meulen

    EJNMMI Radiopharmacy and Chemistry 2017 2:14

    Published on: 25 November 2017

  6. Methodology

    Improving the stability of 11C–labeled L-methionine with ascorbate

    Carbon-11 labeled L-methionine (11C–MET) is a popular tracer used in the clinic for imaging brain tumors with positron emission tomography. However, the stability of 11C–MET in its final formulation is not well d...

    Michael Woods, Leo Leung, Kari Frantzen, Jennifer G. Garrick, Zhengxing Zhang, Chengcheng Zhang, Wade English, Don Wilson, François Bénard and Kuo-Shyan Lin

    EJNMMI Radiopharmacy and Chemistry 2017 2:13

    Published on: 4 October 2017

  7. Position paper

    Position statement on radiopharmaceutical production for clinical trials

    The EU regulation 536/2014 aims to facilitate the experimental use of diagnostic radiopharmaceuticals in particular for GMP requirements and needs to be applied in EU countries. As definitely clarified by this...

    G. Bormans, A. Buck, A. Chiti, M. Cooper, J. Croasdale, M. Desruet, V. Kumar, Y. Liu, I. Penuelas, C. Rossetti, R. Schiavo, S. W. Schwarz and A. D. Windhorst

    EJNMMI Radiopharmacy and Chemistry 2017 2:12

    Published on: 29 September 2017

  8. Methodology

    An efficient preparation of labelling precursor of [11C]L-deprenyl-D2 and automated radiosynthesis

    The synthesis of [11C]L-deprenyl-D2 for imaging of astrocytosis with positron emission tomography (PET) in neurodegenerative diseases has been previously reported. [11C]L-deprenyl-D2 radiosynthesis requires a pre...

    Kevin Zirbesegger, Pablo Buccino, Ingrid Kreimerman, Henry Engler, Williams Porcal and Eduardo Savio

    EJNMMI Radiopharmacy and Chemistry 2017 2:10

    Published on: 24 July 2017

  9. Review

    Sulfur - fluorine bond in PET radiochemistry

    The importance of the sulfur-fluorine bond is starting to increase in modern medicinal chemistry literature. This is due to a better understanding of the stability and reactivity of this moiety depending on th...

    Giancarlo Pascali, Lidia Matesic, Bo Zhang, Andrew T. King, Andrea J. Robinson, Alison T. Ung and Benjamin H. Fraser

    EJNMMI Radiopharmacy and Chemistry 2017 2:9

    Published on: 17 July 2017

  10. Guideline article

    Guidance on validation and qualification of processes and operations involving radiopharmaceuticals

    Validation and qualification activities are nowadays an integral part of the day by day routine work in a radiopharmacy. This document is meant as an Appendix of Part B of the EANM “Guidelines on Good Radiopha...

    S. Todde, P. Kolenc Peitl, P. Elsinga, J. Koziorowski, V. Ferrari, E. M. Ocak, O. Hjelstuen, M. Patt, T. L. Mindt and M. Behe

    EJNMMI Radiopharmacy and Chemistry 2017 2:8

    Published on: 29 June 2017

  11. Review

    Pretargeting for imaging and therapy in oncological nuclear medicine

    Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achi...

    Clément Bailly, Caroline Bodet-Milin, Caroline Rousseau, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré and Jacques Barbet

    EJNMMI Radiopharmacy and Chemistry 2017 2:6

    Published on: 6 June 2017

  12. Research article

    An updated radiosynthesis of [18F]AV1451 for tau PET imaging

    [18F]AV1451 is a commonly used radiotracer for imaging tau deposits in Alzheimer’s disease (AD) and related non-AD tauopathies. Existing radiosyntheses of [18F]AV1451 require complex purifications to provide dose...

    Andrew V. Mossine, Allen F. Brooks, Bradford D. Henderson, Brian G. Hockley, Kirk A. Frey and Peter J. H. Scott

    EJNMMI Radiopharmacy and Chemistry 2017 2:7

    Published on: 6 June 2017

  13. Research article

    47Sc as useful β-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes

    Radiotheragnostics makes use of the same molecular targeting vectors, labeled either with a diagnostic or therapeutic radionuclide, ideally of the same chemical element. The matched pair of scandium radionucli...

    Katharina A. Domnanich, Cristina Müller, Martina Benešová, Rugard Dressler, Stephanie Haller, Ulli Köster, Bernard Ponsard, Roger Schibli, Andreas Türler and Nicholas P. van der Meulen

    EJNMMI Radiopharmacy and Chemistry 2017 2:5

    Published on: 2 June 2017

  14. Research article

    Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography

    The somatostatin receptor subtype 2 (sstr2) is expressed on a majority of luminal breast cancers, however SPECT and scintigraphy imaging with agonistic sstr2 probes has been sub-optimal. High affinity antagoni...

    Iulia Dude, Zhengxing Zhang, Julie Rousseau, Navjit Hundal-Jabal, Nadine Colpo, Helen Merkens, Kuo-Shyan Lin and François Bénard

    EJNMMI Radiopharmacy and Chemistry 2017 2:4

    Published on: 17 April 2017

  15. Research article

    Synthesis, gallium labelling and characterization of P04087, a functionalized phosphatidylserine-binding peptide

    Radiolabeled phosphatidylserine (PS)-binding peptides represent an innovative strategy for molecular imaging of apoptosis and thrombus. The hexapeptide PGDLSR was described as a selective and high affinity lig...

    Rana Ben Azzouna, Alexandre Guez, Khadija Benali, Faisal Al-Shoukr, Walter Gonzalez, Philippe Karoyan, François Rouzet and Dominique Le Guludec

    EJNMMI Radiopharmacy and Chemistry 2017 2:3

    Published on: 7 February 2017

  16. Research

    [64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model

    The chemokine receptor 4 (CXCR4) is an important molecular target for both visualization and therapy of tumors. The aim of the present study was the synthesis and preclinical evaluation of a 64Cu-labeled, CXCR4-t...

    Andreas Poschenrieder, Margret Schottelius, Theresa Osl, Markus Schwaiger and Hans-Jürgen Wester

    EJNMMI Radiopharmacy and Chemistry 2017 2:2

    Published on: 19 January 2017

  17. Research

    Preclinical validations of [18F]FPyPEGCBT-c(RGDfK): a 18F-labelled RGD peptide prepared by ligation of 2-cyanobenzothiazole and 1,2-aminothiol to image angiogenesis

    αVβ3, αVβ5 and α5β1 integrins are known to be involved in carcinogenesis and are overexpressed in many types of tumours compared to healthy tissues; thereby they have been selected as promising therapeutic target...

    Didier J. Colin, James A. H. Inkster, Stéphane Germain and Yann Seimbille

    EJNMMI Radiopharmacy and Chemistry 2016 1:16

    Published on: 25 October 2016

  18. Research

    Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid

    Bisphosphonates have a high adsorption on calcified tissues and are commonly used in the treatment of bone disorder diseases. Conjugates of bisphosphonates with macrocyclic chelators open new possibilities in ...

    M. Meckel, R. Bergmann, M. Miederer and F. Roesch

    EJNMMI Radiopharmacy and Chemistry 2016 1:14

    Published on: 23 September 2016

  19. Review

    Strategies to facilitate the discovery of novel CNS PET ligands

    Positron Emission Tomography (PET), as a non-invasive translatable imaging technology, can be incorporated into various stages of the CNS drug discovery process to provide valuable information for key preclini...

    Lei Zhang and Anabella Villalobos

    EJNMMI Radiopharmacy and Chemistry 2016 1:13

    Published on: 13 September 2016

Previous Page Page 1 of 2 Next Page

Upcoming events

EANM 2018

Neuer Inhalt

EANM sponsorship programme

The EANM Board decided to allocate funds to a dedicated Publication Fee Sponsorship Programme for the entire EJNMMI journal family. Through this programme the EANM will cover the charges that arise for selected open choice publications in the EJNMMI and open access publications in EJNMMI Research, EJNMMI Physics, EJNMMI Radiopharmacy and Chemistry as well as the European Journal of Hybrid Imaging.

Read more

Related websites

Searching for an article? Easily browse the EJNMMI journals on the Nuclear Medicine and Molecular Imaging webportal.